UCB announced that it obtained positive results in its clinical trial with its new drug, RomosozUmab, against osteoporosis. Romosozumab is designed to work by inhibiting the protein sclerostin, thereby increasing bone formation and decreasing bone breakdown.
A Phase III clinical trial to evaluate the safety, tolerability and efficacy of RomosozUmab was performed with 436 women suffering from osteoporosis with high risk for fracture. The effect of RomosozUmab was compared to the current treatment for osteoporosis, i.e. Teriparatide, on the hip bone mineral density. A statistically significant difference was found in favor of RomosozUmab.
